

Gianni L. Editorial: The "Other" signaling of trastuzumab: antibodies are immunocompetent drugs.J Clin Oncol 2008;26:1778–80
More

Herceptin delivers high cure rates for women with HER2-positive early breast cancer

Herceptin extends the lives of women with
HER2-positive metastatic disease
More
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has a poor prognosis, with a high rate of recurrence and short disease-free intervals.
Accurate HER2 testing is essential to correctly identify patients who may benefit from Herceptin.